Fortress Biotech Valuation

Is CNB0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CNB0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CNB0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CNB0's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CNB0?

Key metric: As CNB0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CNB0. This is calculated by dividing CNB0's market cap by their current revenue.
What is CNB0's PS Ratio?
PS Ratio0.6x
SalesUS$81.50m
Market CapUS$46.38m

Price to Sales Ratio vs Peers

How does CNB0's PS Ratio compare to its peers?

The above table shows the PS ratio for CNB0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6x
MDG1 Medigene
2.8x13.3%€20.6m
HPHA Heidelberg Pharma
12.6x16.6%€106.7m
2INV 2invest
8.2xn/a€63.2m
CNW co.don
0.7xn/a€6.5m
CNB0 Fortress Biotech
0.6x55.9%€46.4m

Price-To-Sales vs Peers: CNB0 is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (7.8x).


Price to Sales Ratio vs Industry

How does CNB0's PS Ratio compare vs other companies in the DE Biotechs Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.8.0x21.8%
CNB0 Fortress Biotech
0.6x55.9%US$46.38m
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
CNB0 0.6xIndustry Avg. 8.0xNo. of Companies6PS0612182430+
7 CompaniesEstimated GrowthMarket Cap
Industry Avg.8.0x42.4%
CNB0 Fortress Biotech
0.6x67.3%US$46.38m
No more companies

Price-To-Sales vs Industry: CNB0 is good value based on its Price-To-Sales Ratio (0.6x) compared to the European Biotechs industry average (8x).


Price to Sales Ratio vs Fair Ratio

What is CNB0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CNB0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.6x
Fair PS Ratio5.2x

Price-To-Sales vs Fair Ratio: CNB0 is good value based on its Price-To-Sales Ratio (0.6x) compared to the estimated Fair Price-To-Sales Ratio (5.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies